OncoQR ML
OncoQR ML is a privately held pre-clinical biotech company based in Vienna, Austria, developing novel therapeutic cancer vaccines using its proprietary S-TIR™ (Specific Total Immune Remodulation) technology platform. The company focuses on Active Checkpoint Control Immunotherapy (ACCI) that activates all four natural tumor killing mechanisms of the immune system without side effects. Its lead candidates include OQR100 targeting pancreatic cancer and OQR200 targeting HER2/neu over-expressing breast cancer, both showing in vivo proof of concept. OncoQR ML out-licenses its technology and product candidates, aiming to boost the patient's immune system to fight cancer effectively, positioning itself at the forefront of next-generation cancer immunotherapies.
OncoQR ML
OncoQR ML is a privately held pre-clinical biotech company based in Vienna, Austria, developing novel therapeutic cancer vaccines using its proprietary S-TIR™ (Specific Total Immune Remodulation) technology platform. The company focuses on Active Checkpoint Control Immunotherapy (ACCI) that activates all four natural tumor killing mechanisms of the immune system without side effects. Its lead candidates include OQR100 targeting pancreatic cancer and OQR200 targeting HER2/neu over-expressing breast cancer, both showing in vivo proof of concept. OncoQR ML out-licenses its technology and product candidates, aiming to boost the patient's immune system to fight cancer effectively, positioning itself at the forefront of next-generation cancer immunotherapies.